Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20354)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|
| MDA-MB-468 | MK 1775 | 10.0 | -0.5155 | 0.38863 |
| SUM149PT | AZD6738 | 10.0 | -0.2224 | 0.38785 |
| SUM149PT | THZ1 | 0.316227766 | -0.3148 | 0.38387 |
| HME1 | RO-3306 | 10.0 | -0.0172 | 0.38377 |
| HME1 | THZ1 | 0.316227766 | -0.2065 | 0.38302 |
| SUM1315MO2 | Alvocidib | 1.0 | -0.7885 | 0.38253 |
| SUM159PT | MK 1775 | 10.0 | -0.1288 | 0.38197 |
| HME1 | BMS-265246 | 3.16227766 | -0.0547 | 0.38150 |
| MCF 10A | LY3023414 | 3.16227766017 | 0.0431 | 0.38049 |
| HME1 | Ulixertinib | 10.0 | 0.0078 | 0.37986 |
| HME1 | Ulixertinib | 10.0 | 0.0167 | 0.37968 |
| CAL-85-1 | THZ1 | 1.0 | -0.5032 | 0.37632 |
| CAL-85-1 | MK 1775 | 10.0 | -0.5298 | 0.37240 |
| SUM149PT | RO-3306 | 10.0 | -0.1552 | 0.37190 |
| AU565 | THZ531 | 1.0 | -0.4980 | 0.37159 |
| HCC38 | MK 1775 | 3.16227766017 | -0.2744 | 0.37151 |
| HME1 | MK 1775 | 10.0 | -0.1322 | 0.37117 |
| MDA-MB-134-VI | THZ531 | 0.316227766017 | -0.8292 | 0.37046 |
| HME1 | BMS-265246 | 1.0 | -0.0693 | 0.36937 |
| MDA-MB-361 | THZ531 | 0.1 | -0.7989 | 0.36894 |
| HME1 | THZ531 | 1.0 | -0.1752 | 0.36757 |
| SUM149PT | THZ1 | 1.0 | -0.3915 | 0.36547 |
| HCC1954 | THZ531 | 1.0 | -0.3218 | 0.36543 |
| SK-BR-3 | MK 1775 | 10.0 | -0.5356 | 0.36461 |
| HCC1395 | THZ1 | 1.0 | -0.7322 | 0.36460 |